Australia and New Zealand Anemia in Pregnancy Market Report and Forecast 2025-2034

Australia and New Zealand Anemia in Pregnancy Market Outlook

The Australia and New Zealand anemia in pregnancy market size is expected to grow at a CAGR of 8.6% during the forecast period of 2025-2034. The growth of the market is likely to be driven by increasing incidence of pregnancies and rising awareness programs around the condition.

Australia and New Zealand Anemia in Pregnancy Market Overview

On average, the human body requires around five liters of blood. Towards the end of pregnancy, the requirement reaches around seven to eight liters. The body requires about thrice as much iron during pregnancy, and when the requirement is not met promptly, women tend to develop anemia. Approximately 40% of women begin their pregnancy with depleted iron levels in the body. Folate (folic acid) and vitamin B12 deficiency, pre-eclampsia and sickle cell disease can also lead to anemia in pregnancy.

Australia and New Zealand anemia in pregnancy market demand is driven by growing focus on alleviating pregnancy complications in both the mother as well as the fetus. Anemia is associated with growth in cesarean delivery, postpartum depression, perinatal blood transfusion and even low birth weight, and preterm birth in neonates as well. Low iron levels are also linked neurological impairments that may persist even in adulthood. Hence, there has been significant emphasis on treating anemia in pregnancy.

The market is driven by rising initiatives to spread awareness around the condition, along with growth in research and development activities to develop enhanced and diverse alternatives for patients.

Research Activities to Develop Safe Alternatives to Contribute to the Australia and New Zealand Anemia in Pregnancy Market Share

Dietary iron is often hard to absorb in the body, thus, it can be difficult to uptake sufficient iron content from the food sources a person consumes. To offer improved alternatives to patients, scientists have been exploring new and innovative methods in different routes of administration. To treat anemia associated with inflammatory bowel disease in pregnancy, a study presented at United European Gastroenterology Week 2023 demonstrated positive effects of ferric maltol. Administered in 27 pregnant women expecting to give birth in April or May 2023, the drug proceeded without complications and led to birth of healthy infants except for 2 patients.

Iron supplementation is one of the most common and recommended treatment methods for anemia in pregnancy. For high doses, oral iron (ferrous sulphate) is the current standard treatment, owing effective, inexpensive, and readily available concentration. However, higher, and frequent dosage has led to gastrointestinal perturbation, resulting in decreased adherence to therapy. As a result, research activities for alternative therapies have been on the rise. Intravenous iron therapy is emerging as a significant option, especially for catering women in their second or third trimesters. Low-molecular weight iron dextran, ferric derisomaltose, or ferric carboxymaltose are commonly preferred for intravenous therapies. Increasing advancements in biotechnology domain are poised to boost the Australia and New Zealand anemia in pregnancy market growth in the coming years.

Rise in Initiatives to Spread Awareness

A survey conducted in November 2023 revealed that most Australians (24%) were unaware or had limited information of common iron deficiency related symptoms. Around 90% of them were unaware of ice cravings, dizziness (57%) and shortness of breath (81%). Therefore, there has been significant emphasis on educating the public, particularly pregnant women, to combat the repercussions that may align with the deficiency. ‘Take Iron Seriously’ is an awareness campaign launched to offer information to easily detect the condition on early stages so as to facilitate appropriate treatment in due time. The increasing arrangement of such programs is anticipated to drive the market growth during the forecast period.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Australia and New Zealand Anemia in Pregnancy Market Segmentation

Market Breakup by Cause

• Folic Acid Deficiency

• Iron Deficiency

• Vitamin B12 Deficiency

• Others

Market Breakup by Treatment

• Iron Products

• Folic Acid Supplementation

• Others

Market Breakup by Weeks

• < 13 Weeks

• 13-27 Weeks

• ≥28 Weeks

Market Breakup by Route of Administration

• Oral

• Intravenous

• Intramuscular

Market Breakup by Distribution Channel

• Hospital Pharmacy

• Retail Pharmacy

• Online Pharmacy

• Others
   

Market Breakup by End User

• Hospitals

• Specialty Clinics

• Home Healthcare

• Others

Market Breakup by Country

• Australia

• New Zealand

Australia and New Zealand Anemia in Pregnancy Market Regional Analysis

To prevent mortalities associated with anemia, there has been significant emphasis on diagnosing the condition early in pregnancy. Therefore, the region has been witnessing significant development in well-equipped public hospitals and clinics. In the forecast period, Australia is poised to lead the Australia and New Zealand anemia in pregnancy market share, owing to rising prevalence for personalized care.

New Zealand is also poised to witness substantial growth which can be attributed to rising emergence of technology driven start-ups along with increased collaboration between pharmaceutical companies and research institutions.

Australia and New Zealand Anemia in Pregnancy Market: Competitor Landscape

In June 2023, Janssen Pharmaceutical (a division of Johnson & Johnson) announced positive results for Nipocalimab, a drug for treating hemolytic disease of the fetus and newborn (HDFN) in pregnant individual at high risk of developing the condition. The drug is the only therapy for HDFN wherein the foetus may develop anemia due to incompatible blood type with the pregnant individual. It showed promising results in the Phase 2 open-label UNITY clinical trial.

The key features of the Australia and New Zealand anemia in pregnancy market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Viatris Inc.

• Aspen Pharmacare Australia Pty Ltd

• PharmaCare Laboratories Australia

• AFT Pharmaceuticals

• Bayer AG

• A Nelson & Co Ltd

• BLACKMORES

• Care Pharma

• Amgen Inc.

• Hoffmann-La Roche Ltd.

• AMAG Pharmaceuticals

• Rockwell Medical

• Vifor Pharma Management Ltd.

• Janssen Pharmaceuticals, Inc.

• Teva Pharmaceutical Industries Ltd.

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report

Australia and New Zealand Anemia in Pregnancy Market Report Snapshots

Australia and New Zealand Anemia in Pregnancy Market Size

Australia and New Zealand Anemia in Pregnancy Market Regional Analysis

Australia and New Zealand Anemia in Pregnancy Treatment Companies